Evidence map›Paper›PMID 41404416›Full record

ArticleFrontiers in bioinformatics2025

Functional and structural impacts of oncogenic missense variants on human polo-like kinase 1 protein.

Gayatri Munieswaran, Venkatraman Manickam

Abstract read
In one paragraph

Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gayatri MunieswaranSchool of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Venkatraman ManickamSchool of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The polo-like kinase 1 (PLK1), a master key mitotic regulator, is frequently expressed in various types of cancers and associated with poor prognosis. The missense mutations in PLK1 may compromise its structural integrity and functional interactions, contributing to tumorigenesis. Methods: This study utilized a comprehensive computational pipeline to identify deleterious missense variants across multiple cancers. 207 non-synonymous single nucleotide polymorphisms (nsSNPs) were retrieved from cBioPortal, and 11 high-risk variants were prioritized using functional and structural prediction tools, such as SIFT, PolyPhen-2, I-mutant 2.0, and so on. Prognostic prevalence was evaluated via Kaplan-Meier survival analysis, and functional networks were explored using STRING. The structural dynamics of modeled mutations were analyzed through molecular dynamic simulations over 100 ns. Results: The kinase domain mutations such as L244F, R293C, and R293H and polo-box domain mutations such as A520T were found to cause deviations in structural stability, flexibility, solvent exposure, and compactness compared to wild-type. Further, PLK1 overexpression correlated with poor overall survival of patient outcomes in many types of cancers, including breast, liver, lung, kidney, and pancreatic cancers. Protein-protein interaction revealed PLK1's involvement in oncogenic pathways. Discussion: The study highlights the structural and functional implications of oncogenic PLK1 mutations, emphasizing their role in cancer progression. Integrating predictive and dynamic exploration approaches facilitates prioritization of variants with potential clinical relevance. Conclusion: The nsSNPs in PLK1 may perturb conformational stability and functions of the protein. Further experimental validation and discovery of novel inhibitors might develop mutation-specific interventions in precision oncology.

Indexed as

biomarkercancermolecular dynamic simulationnsSNPsplk1

Identifiers

PMID41404416
PMCPMC12704984

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.